Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCAT 2024 | HemaFAIR: an EU-funded medical informatics project

Petros Kountouris • 2 Oct 2024
ASCAT 2024
General Rare Diseases

In this video, Petros Kountouris, PhD, The Cyprus Institute of Neurology & Genetics, Lefkosia, Cyprus, introduces HemaFAIR, a medical informatics project funded by the European Commission. This initiative focuses on the application of FAIR (findable, accessible, interoperable, reusable) principles in rare hematological disease research. This interview took place at the 19th Annual Scientific Conference of the Academy for Sickle Cell and Thalassaemia (ASCAT 2024) in London, UK.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

Research funding: Agios Pharmaceuticals.

More from Petros Kountouris

The INHERENT network: advancing understanding of genetic modifiers in hemoglobinopathies
1:31
The INHERENT network: advancing understanding of genetic modifiers in hemoglobinopathies
Petros Kountouris • 2 Oct 2024
The HELIOS network: disseminating knowledge on hemoglobinopathies
1:18
The HELIOS network: disseminating knowledge on hemoglobinopathies
Petros Kountouris • 2 Oct 2024

Related Videos

Key principles for implementing AI tools into clinical practice
3:19
Key principles for implementing AI tools into clinical practice
Adrián Mosquera Orgueira • 24 Sep 2026
Current role of AI in hematology/oncology: separating the hype from reality
2:54
Current role of AI in hematology/oncology: separating the hype from reality
Adrián Mosquera Orgueira • 24 Sep 2026
Addressing the risk of over-reliance on AI for clinical decision-making
2:25
Addressing the risk of over-reliance on AI for clinical decision-making
Adrián Mosquera Orgueira • 24 Sep 2026
Phase III CARES: survival and cardiovascular outcomes with anselamimab in cardiac AL amyloidosis
2:19
Phase III CARES: survival and cardiovascular outcomes with anselamimab in cardiac AL amyloidosis
Ashutosh Wechalekar • 9 Sep 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals